

April 30, 2020
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

Chimerix Receives FDA Clearance for Rolling Submission of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox

TOKYO, Japan, April 30, 2020 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio"), which in-licensed the antiviral drug brincidofovir (BCV) from Chimerix Inc. (Headquarters: Durham, NC, "Chimerix") on September 30, 2019 and is preparing to initiate a global study of BCV, today announced that Chimerix announced on April 28, 2020 that Chimerix has received clearance from the U.S. Food and Drug Administration (FDA) for a rolling submission of its New Drug Application (NDA) for the approval of brincidofovir (BCV) as a medical countermeasure for smallpox.

Chimerix is developing BCV as a potential medical countermeasure for smallpox under an ongoing collaboration and funding provided by the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services.

For more information, please see Chimerix's website:

<https://ir.chimerix.com/press-releases>

Mr. Fuminori Yoshida, President and Chief Executive Officer of SymBio, stated: "SymBio has the exclusive worldwide license to develop, manufacture, and commercialize BCV in all human indications excluding the prevention and treatment of smallpox. The clearance Chimerix received to begin the rolling submission of its NDA for BCV as a medical countermeasure for smallpox is also an important milestone for SymBio."

About Chimerix

Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases. Its two clinical-stage development programs are dociparstat sodium (DSTAT) and brincidofovir (BCV).

BCV is an antiviral drug candidate in development as a medical countermeasure for smallpox. For further information, please visit the Chimerix website, www.chimerix.com.

About the Global License Agreement for Brincidofovir

SymBio entered into an exclusive global license agreement with Chimerix Inc. (Headquarters: Durham, NC, "Chimerix") for brincidofovir (BCV) on September 30, 2019. Under the terms of the agreement, Chimerix grants SymBio exclusive worldwide rights to develop, manufacture, and commercialize BCV in all human indications, excluding the prevention and treatment of smallpox.

For further information, please see the SymBio's press release dated October 1, 2019,

<https://www.symbiopharma.com/news/20191001.pdf>

About SymBio Pharmaceuticals Limited

SymBio Pharmaceuticals Limited was established in March, 2005 by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May, 2016 the Company incorporated its wholly-owned subsidiary in the U.S., called SymBio Pharma USA, Inc. (Headquarters: Menlo Park, California, President: Mr. Fuminori Yoshida). The Company's underlying corporate mission is to "deliver hope to patients in need" as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs.